First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma
- 28 February 2003
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 30 (1), 9-15
- https://doi.org/10.1053/sonc.2003.50023
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-TreatmentJournal of Clinical Oncology, 2000
- Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphomaBlood, 2000
- Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphomaAnnals of Oncology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's LymphomaBlood, 1997
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994
- Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation.Journal of Clinical Oncology, 1992
- Histologic conversion in the non-Hodgkin's lymphomas.Journal of Clinical Oncology, 1983